Zilucoplan’s Edge in Complement Inhibition in Myasthenia Gravis: Miriam Freimer, MD
Understanding How Complement C5 Inhibitors Work in MG: Miriam Freimer, MD
Addressing Myasthenia Gravis Diagnostic Delays and Access Barriers: Marla Black Morgan, MD
Expanding Hope for Pediatric Myasthenia Gravis: Jonathan Strober, MD
Accurate Diagnosis of Myasthenia Gravis in Pediatric Patients Is Challenging: Jonathan Strober, MD
Barriers to Timely Diagnosis of Generalized Myasthenia Gravis: Marla Black Morgan, MD
Pediatric Patients With Myasthenia Gravis Need More Treatment Options: Jonathan Strober, MD
Early Diagnosis Vital to Myasthenia Gravis Treatment: Richard J. Nowak, MD, MS
Delays, Disparities in gMG Diagnosis Among Minority Patients: Marla Black Morgan, MD
52-Week MINT Data Confirm Inebilizumab Benefit in AChR+ gMG: Richard Nowak, MD, MS
Rozanolixizumab Remains Consistently Safe, Effective for gMG
Sugammadex Safe, Effective Post Surgery in Myasthenia Gravis
Clinical Features Vary Across Myasthenia Gravis Foundation Classes
Enhancing Myasthenia Gravis Care With AI-Powered Telemedicine
COVID-19 Exacerbations in Myasthenia Gravis Linked to Severity
Rozanolixizumab Effective in Patients With MuSK MG, Analysis Shows
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.